PLPatrik Larsson

Patrik Larsson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Patrik Larsson has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Ernesto Sparrelid

    Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital , Stockholm

    6 shared publications
  • Poya Ghorbani

    Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital , Stockholm

    4 shared publications
  • Ajnon Khawaja

    Department of Clinical Sciences, Interventions and Technology, Division of Surgery and Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

    3 shared publications
  • Diana Cheraghi

    Department of Clinical Sciences, Interventions and Technology, Division of Surgery and Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

    3 shared publications
  • Oskar Swartling

    Department of Clinical Sciences, Interventions and Technology, Division of Surgery and Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

    3 shared publications
  • Poya Ghorbani

    Division of Surgery, Department of Clinical Science, Intervention and Technology, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden

    3 shared publications

Latest Publications

  • Open Access

    Multiple R1 margins are associated with shorter overall survival: national register-based study on pancreatic cancer

    by Patrik Larsson, Carlos Fernández Moro, Melroy D’SOuza, Bobby Tingstedt, Ernesto Sparrelid, Poya Ghorbani

    Background: Resection status is associated with overall survival among patients operated on for pancreatic ductal adenocarcinoma (PDAC). This study investigated whether the number of R1 margins is associated with shorter survival. Methods: Adult patients who underwent pancreatoduodenectomy for primary resectable PDAC between 2017 and 2024 recorded in the Swedish National Pancreatic Registry were included. Overall survival was analysed according to overall R status and the number of R1 margins. Overall survival was analysed using Kaplan–Meier estimates, Cox regression analysis for estimated adjusted survival time, and Laplace regression for analysis of percentile distribution. Results: Overall, 1043 patients were included, 398 patients (38.2%) with R0 and 645 patients (61.8%) with R1 margins. The adjusted median survival was 8.2 (95% confidence interval (c.i.) −12.0 to −4.3) months shorter for patients with R1 versus R0 margins, with a progressively shorter survival with a higher number of R1 margins. Specifically, compared with R0 margins, the adjusted median survival for one, two and three or more R1 margins was 4.6 (95% c.i. −10.2 to 1.0), 6.7 (95% c.i. −11.9 to −1.5), and 12.4 (95% c.i. −16.5 to −8.3) months shorter, respectively. Conclusions: Patients with R1 margins had an adjusted median survival that was 8 months shorter than patients with R0 margins. An increased number of R1 margins was associated with shorter survival. These results suggest that the current practice of reporting binary R status is insufficient, and future guidelines should consider revising this routine and adopt a standardized, detailed margin assessment protocol.

  • Open Access

    Aspects on patient selection among patients with pancreatic cancer

    by Patrik Larsson

    Pancreatic cancer is one of the deadliest forms of cancer. Despite the last decades improvements in health care, patients with pancreatic cancer still have a poor prognosis. There is a need for finding new treatments. It is equally important to improve our knowledge on how to use available techniques and treatments. The overall aim of this thesis was to help us become better at giving the right treatment for the right patient. The thesis explored several aspects of the reality facing patients with pancreatic cancer in five different studies. Study I, II and III studied treatment outcomes, study IV and V investigated diagnostic methods.Study I and II investigated the association between comorbidities and postoperative outcomes after pancreatoduodenectomy. Both studies were single-centre historical cohort studies and included all patients operated with pancreatoduodenectomy between the years 2008 and 2019. In study I, patients with chronic heart diseases were compared to patients without these comorbidities. Study II investigated patients with a preoperative diagnosis of chronic obstructive pulmonary disease (COPD) to patients without COPD. Study I found that one-fourth of all operated patients had a preoperative chronic heart disease. These patients had an increased odds ratio for major postoperative complications, intensive care unit admission and longer hospitalization. This association was highest for patients with atrial fibrillation and heart failure. Study II found that patients with COPD had an increased odds ratio for clinically significant postoperative pancreatic fistula. Patients with COPD had a higher incidence of one-year mortality although it was not possible to exclude that this difference was due to chance.Study III investigated the outcome for patients with locally advanced pancreatic cancer (LAPC). The study used a population-based cohort to attempt to reflect the complete source population. The outcomes were analysed as intention-to-treat analysis. Patients fulfilling the National comprehensive cancer network criteria for LAPC, residing in the Stockholm area discussed at the multidisciplinary tumour board between November 2017 and December 2021 were included. During the study period, 134 fulfilled all inclusion criteria. This corresponded to an incidence rate of 1.46 patients with LAPC per 100 000 person-years. There was no difference in survival between patients recommended neoadjuvant chemotherapy (with and without surgery) to palliative chemotherapy from time of diagnosis. The group of patients that responded to chemotherapy and underwent resection had a longer overall survival compared to patients that did not respond to chemotherapy. It was not possible to conclude if this difference was mainly due to surgery or differences in tumour biology.Study IV investigated the possible benefit of performing staging laparoscopy for improved tumour staging and patient outcome. It was a systematic review with meta-analyses on studies among patients with localised disease. It included more than five thousand patients globally. The study found that the overall yield for staging laparoscopy was fifteen per cent, corresponding to a number needed to test of seven. The negative predictive value was 97% (84%-99%). The yield was highest among patients with LAPC. There were only three studies reporting on postoperative outcomes. This hindered any statistical modelling. The results in these studies implied better patient outcome among patients with metastases found with staging laparoscopy compared to laparotomy.Study V investigated the association between the number of margins without radical histopathological status (R1) in the resected specimen and overall survival. Patients were identified from the Swedish national periampullary and pancreatic cancer registry. All patients operated with pancreatoduodenectomy for pancreatic ductal adenocarcinoma between the years 2017 and 2024 were included. Survival was analysed as complete case and with multiple imputation. The analyses included Laplace regression, cox proportional hazard regression and the Kaplan Meier method. The study found that most patients, 62%, had an overall R status defined as R1. The adjusted median survival was eight months shorter among patients with an overall R1 compared to R0. In all analyses, the survival was progressively shorter with an increasing number of margins defined as R1 compared to R0.In conclusion, this thesis found that I) Among patients deemed fit enough to undergo surgery, patients with chronic heart disease and II) COPD had increased risks of postoperative complications, III) Among patients with LAPC in a population-based cohort, only a small subgroup of patients treated with the intent to reach surgery had a sufficient response on chemotherapy to undergo surgery, IV) Current evidence support staging laparoscopy as a diagnostic tool for improved tumour staging, V) Analysing and reporting the R status ordinally in the pathology report holds clinically relevant information.List of scientific papersI. Preoperative heart disease and risk for postoperative complications after pancreatoduodenectomy. Larsson P, Feldt K, Holmberg M, Swartling O, Sparrelid E, Klevebro F, Ghorbani P. HPB (Oxford). 2022;24(11):1854-60. https://doi.org/10.1016/j.hpb.2022.07.002II. The impact of chronic obstructive pulmonary disease on risk for complications after pancreatoduodenectomy - a single centre cohort study. Larsson P, Swartling O, Perri G, Vaez K, Holmberg M, Klevebro F, Gilg S, Sparrelid E, Ghorbani P. HPB (Oxford). 2025;27(1):87-93. https://doi.org/10.1016/j.hpb.2024.10.005III. Assessment of Outcomes by Intention-to-Treat Comparison for Locally Advanced Pancreatic Cancer: A Population-Derived Cohort Study. Larsson P, Swartling O, Cheraghi D, Khawaja A, Soreide K, Sparrelid E, Ghorbani P. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-16291-9IV. Yield and clinical benefit of staging laparoscopy for occult...

  • Open Access

    Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies

    by Thomas F. Stoop, Kishan R.D. Lutchman, Rutger T. Theijse, Patrik Larsson, Atsushi Oba, Bas Groot Koerkamp, Casper H.J. van Eijck, Christopher L. Wolfgang, Elena Rangelova, Giovanni Marchegiani, et al.


  • ASO Visual Abstract: Assessment of Outcomes by Intention-to-Treat Comparison for Locally Advanced Pancreatic Cancer: A Population-Derived Cohort Study

    by Patrik Larsson, Oskar Swartling, Diana Cheraghi, Ajnon Khawaja, Kjetil Soreide, Ernesto Sparrelid, Poya Ghorbani


  • Open Access

    ASO Author Reflections: Population-Derived Outcome by Treatment-Intent for LAPC

    by Patrik Larsson, Oskar Swartling, Diana Cheraghi, Ajnon Khawaja, Kjetil Søreide, Ernesto Sparrelid, Poya Ghorbani

  • Open Access

    The impact of chronic obstructive pulmonary disease on risk for complications after pancreatoduodenectomy - a single centre cohort study

    by Patrik Larsson, Oskar Swartling, Giampaolo Perri, Kaveh Vaez, Marcus Holmberg, Fredrik Klevebro, Stefan Gilg, Ernesto Sparrelid, Poya Ghorbani


  • Open Access

    Assessment of Outcomes by Intention-to-Treat Comparison for Locally Advanced Pancreatic Cancer: A Population-Derived Cohort Study

    by Patrik Larsson, Oskar Swartling, Diana Cheraghi, Ajnon Khawaja, Kjetil Soreide, Ernesto Sparrelid, Poya Ghorbani

    Background: The overall treatment response among patients with locally advanced pancreatic cancer (LAPC) is poorly understood as most studies report solely on resected patients. We aimed to investigate the outcomes in patients with LAPC as an intention-to-treat-analysis from the time of diagnosis from a complete source population. Patients and Methods: An observational cohort study in a population-defined region within a universal healthcare system. All consecutive patients discussed at multi-disciplinary tumour board (MDT), aged ≥ 18 years and diagnosed with LAPC were included. Exposure was set as recommended treatment by MDT (i.e. upfront surgery, neoadjuvant therapy, palliative treatment or best supportive care). Outcome measures were overall survival analysed by Kaplan–Meier survival estimates and multivariable analyses using logistic regression for odds ratios (OR) and Cox proportional hazard analysis for hazard ratios (HR). Results: In total, 8803 MDT events (6055 unique patients) with pancreatic disease were held during the study period. Some 1436 (24%) had pancreatic cancer, of which 162 (11%) had LAPC and 134 met the population-defined criteria. In overall survival analyses, the patients who were recommended neoadjuvant therapy (± surgery) demonstrated no significant difference to palliative chemotherapy (median 11.0 months vs. 11.8 months; p = 0.226). In multivariable analysis, adjusted OR for overall survival comparing the treatment groups was 0.27 (95% CI 0.02–3.29, p = 0.306) and Cox proportional HR 0.96 (95% CI 0.58–1.59, p = 0.865). Conclusions: In patients with LAPC, survival was not statistically different between those recommended for attempt at neoadjuvant (± surgery) compared with those recommended palliative chemotherapy. The findings suggest that conversion/downstaging chemotherapy is successful in only a select few.


  • Open Access

    Preoperative heart disease and risk for postoperative complications after pancreatoduodenectomy

    by Patrik Larsson, Kari Feldt, Marcus Holmberg, Oskar Swartling, Ernesto Sparrelid, Fredrik Klevebro, Poya Ghorbani